Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.44 |
| ▸ | PPARG | P37231 | 7/20 | 0.44 |
| ▸ | PPARD | Q03181 | 7/20 | 0.44 |
| ▸ | PPARA | Q07869 | 7/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | FABP4 | P15090 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18260639 | 1.00 | GPR84 (0.44) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL30413 | 1.00 | GPR84 (0.44) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL1273217 | 1.00 | GPR84 (0.44) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL5495040 | 1.00 | GPR84 (0.44) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL5490197 | 1.00 | GPR84 (0.44) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL253962 | 1.00 | GPR84 (0.44) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL5395520 | 0.98 | AKR1B1 (0.42) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL1470099 | 0.91 | PPARG (0.53) | PPARGPPARDPPARATSHRPTPN1 | |
| SCHEMBL456745 | 0.91 | PPARG (0.53) | PPARGPPARDPPARATSHRPTPN1 | |
| SCHEMBL5418693 | 0.81 | GPR84 (0.36) | GPR84PPARGPPARDPPARAHDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1997 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4398882-A1 | LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY | BioNTech SE (DE) | 2024-07-17 | — | — | EP | claimed |
| US-12037600-B2 | Transfection complexes and methods of using the same | MOLECULAR TRANSFER, INC. (US) | 2024-07-16 | — | — | US | claimed |
| EP-4382094-A1 | ATHEROSCLEROSIS-TARGETED LIPOSOME NANOCARRIER DELIVERY SYSTEM AND PREPARATION METHOD THEREFOR | Beijing Inno Medicine Co., Ltd. (CN) | 2024-06-12 | — | — | EP | claimed |
| US-20240182412-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2024-06-06 | — | — | US | claimed |
| US-20240180940-A1 | MPLA COMPOSITIONS AND METHODS OF USE | REVELATION BIOSCIENCES, INC. | 2024-06-06 | — | — | US | claimed |
| WO-2024091615-A1 | METHODS OF ADJUVANT TREATMENT FOR ALLERGY IMMUNOTHERAPY | REVELATION BOSCIENCES, INC. (US) | 2024-05-02 | — | — | WO | claimed |
| EP-4346766-A1 | METHODS OF TREATING OR PREVENTING ALLERGIES AND CHRONIC NASAL CONGESTION | Revelation Biosciences, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| EP-4346896-A1 | MPLA COMPOSITIONS AND METHODS OF USE | Revelation Biosciences, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| US-20240108685-A1 | ORAL LIPOSOMAL COMPOSITIONS | RENAULT JEAN YVES (FR) | 2024-04-04 | — | — | US | claimed |
| WO-2024056062-A1 | STEROID HORMONE-PHOSPHOLIPID COMPOSITION AND PREPARATION METHOD THEREFOR | 长春金赛药业有限责任公司 | 2024-03-21 | — | — | WO | claimed |
| EP-0671905-A1 | STABLE PROTEIN: PHOSPHOLIPID COMPOSITIONS AND METHODS | AMGEN INC. (US) | 1995-09-20 | — | — | EP | claimed |
| EP-0665743-A1 | INTERDIGITATION-FUSION LIPOSOMES AND GELS | THE LIPOSOME COMPANY, INC. (US) | 1995-08-09 | — | — | EP | claimed |
| WO-1995009611-A2 | STABLE PROTEIN: PHOSPHOLIPID COMPOSITIONS AND METHODS | AMGEN INC. (US) | 1995-04-13 | — | — | WO | claimed |
| WO-1994008565-A9 | INTERDIGITATION-FUSION LIPOSOMES AND GELS | — | 1994-07-07 | — | — | WO | claimed |
| WO-1994008565-A1 | INTERDIGITATION-FUSION LIPOSOMES AND GELS | THE LIPOSOME COMPANY, INC. (US) | 1994-04-28 | — | — | WO | claimed |
| EP-0510086-A4 | INTERDIGITATION-FUSION LIPOSOMES AND GELS | — | 1993-03-17 | — | — | EP | claimed |
| EP-0510086-A1 | INTERDIGITATION-FUSION LIPOSOMES AND GELS. | LIPOSOME CO INC (US) | 1992-10-28 | — | — | EP | claimed |
| US-5100591-A | Microsuspensioin, phosphatides, polyene macrolide antibiotic | MEDGENIX GROUP S.A. (BE) | 1992-03-31 | — | — | US | claimed |
| WO-1991010422-A1 | INTERDIGITATION-FUSION LIPOSOMES AND GELS | THE LIPOSOME COMPANY, INC. (US) | 1991-07-25 | — | — | WO | claimed |
| US-4619794-A | Spontaneous preparation of small unilamellar liposomes | CIBA-GEIGY CORPORATION (US) | 1986-10-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108685-A1 | ORAL LIPOSOMAL COMPOSITIONS | SGMS1, SGMS2, CD14 | GPR84 520/4885PPARG 465/4885PPARD 273/4885 |
| US-20240182412-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | GPR84 2192/4885PPARG 2631/4885PPARD 2722/4885 |
| US-12037600-B2 | Transfection complexes and methods of using the same | TIAL1, NPC1L1, LIPA | GPR84 2848/4885PPARG 639/4885PPARD 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.